1. Retinal Organoids derived from hiPSCs of an AIPL1-LCA Patient Maintain Cytoarchitecture despite Reduced levels of Mutant AIPL1
- Author
-
Slaven Erceg, Ana Artero Castro, Nicolás Cuenca, Anand Swaroop, Marta Corton, Carmen Ayuso, Visvanathan Ramamurthy, Dunja Lukovic, Linn Gieser, Carlota Davó-Martínez, Daniella Munezero, Koray Dogan Kaya, Universidad de Alicante. Departamento de Fisiología, Genética y Microbiología, and Neurobiología del Sistema Visual y Terapia de Enfermedades Neurodegenerativas (NEUROVIS)
- Subjects
0301 basic medicine ,Mutant ,Induced Pluripotent Stem Cells ,Leber Congenital Amaurosis ,lcsh:Medicine ,Stem-cell differentiation ,030105 genetics & heredity ,Biology ,Biología Celular ,Retina ,Article ,Cell Line ,Mutant AIPL1 ,03 medical and health sciences ,chemistry.chemical_compound ,Organoid ,Reduced levels ,Humans ,lcsh:Science ,Eye Proteins ,Adaptor Proteins, Signal Transducing ,hiPSCs ,Multidisciplinary ,Effector ,lcsh:R ,Phosphodiesterase ,Retinal organoids ,Retinal ,In vitro ,3. Good health ,Cell biology ,Organoids ,AIPL1-LCA patient ,030104 developmental biology ,chemistry ,Cell culture ,3',5'-Cyclic-AMP Phosphodiesterases ,Mutation ,lcsh:Q ,Cytoarchitecture ,Carrier Proteins ,Visual phototransduction - Abstract
Aryl hydrocarbon receptor-interacting protein-like 1 (AIPL1) is a photoreceptor-specific chaperone that stabilizes the effector enzyme of phototransduction, cGMP phosphodiesterase 6 (PDE6). Mutations in the AIPL1 gene cause a severe inherited retinal dystrophy, Leber congenital amaurosis type 4 (LCA4), that manifests as the loss of vision during the first year of life. In this study, we generated three-dimensional (3D) retinal organoids (ROs) from human induced pluripotent stem cells (hiPSCs) derived from an LCA4 patient carrying a Cys89Arg mutation in AIPL1. This study aimed to (i) explore whether the patient hiPSC-derived ROs recapitulate LCA4 disease phenotype, and (ii) generate a clinically relevant resource to investigate the molecular mechanism of disease and safely test novel therapies for LCA4 in vitro. We demonstrate reduced levels of the mutant AIPL1 and PDE6 proteins in patient organoids, corroborating the findings in animal models; however, patient-derived organoids maintained retinal cell cytoarchitecture despite significantly reduced levels of AIPL1. This work was supported by Institute of Health Carlos III (ISCIII)/ ERDF (European Research Development Fund), Spain, ((PI16/00409 (DL); DL, AAC, and SE are members of PRB3 supported by a grant (PT17/0019/0024) of the PE I + D + i 2013–2016, funded by ISCIII and ERDF. The work was also supported by ISCIII-ERDF (PI16/00425), CIBERER 06/07/0036, IIS-FJD Biobank PT13/0010/0012, RAREGENOMICS funded by Regional Government of Madrid, (CAM, B2017/BMD3721) and ERDF, the University Chair UAM-IIS-FJD of Genomic Medicine, the Spanish National Organization of the Blind (ONCE), the Spanish Fighting Blindness Foundation (FUNDALUCE), and the Ramon Areces Foundation. MC is supported by the Miguel Servet Program (CPII17_00006) from ISCIII. DL is supported by Miguel Servet I Program (CP18/00033). VR is supported by National Institute of Health (R01 EY028035, R01 EY025536). Transcriptome profiling and analyses were supported by the Intramural Research Program of the National Eye Institute (ZIAEY000450, ZIAEY000474) and utilized the high-performance computational capabilities of the Biowulf Linux cluster at NIH (http://biowulf.nih.gov).
- Published
- 2019